2020 Fiscal Year Final Research Report
Personalized therapy for mercaptopurine by measuring metabolites in DNA in children with leukemia
| Project/Area Number |
18K06756
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | National Institute of Health Sciences (2020)
Kitasato University (2018-2019) |
|---|
Principal Investigator |
Tanaka Yoichi 国立医薬品食品衛生研究所, 医薬安全科学部, 主任研究官 (40525341)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | 6-メルカプトプリン / 白血病 / 小児 / DNA / deoxy thioguanosine / NUDT15 |
|---|
| Outline of Final Research Achievements |
To adjust 6-mercaptopurine (6-MP) therapy for children with acute lymphoblastic leukemia, we measured 6-MP metabolite in blood cells and DNA during maintenance therapy and evaluated the association among 6-MP metabolite levels, genetic variations of 6-MP metabolism enzymes and 6-MP dose. 6-MP metabolite levels were associated with 6-MP intolerability in each cells. And 6-MP metabolite level inserted into DNA was influence on NUDT15 genetic variants.
|
| Free Research Field |
医療薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
小児急性リンパ性白血病における6-MPによる治療の感受性には、DNAに取り込まれた6-MP代謝物量が関連している。また患者の持つNUDT15遺伝子多型によって、DNAへの取り込まれやすさが異なる。患者の持つNUDT15遺伝子多型および6-MP代謝物濃度の測定を併せて検討する事で、治療効果が期待できるが副作用が少ない患者個々に合わせた6-MPによる治療を提供することができると考えられる。
|
